VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 3 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2018. The put-call ratio across all filers is - and the average weighting 1.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $3,254,000 | +57.2% | 140,000 | +7.7% | 1.25% | +29.5% |
| Q1 2018 | $2,070,000 | -0.4% | 130,000 | +30.0% | 0.97% | +25.3% |
| Q4 2017 | $2,078,000 | -17.1% | 100,000 | -42.9% | 0.77% | -9.6% |
| Q3 2017 | $2,508,000 | -40.8% | 175,000 | -28.6% | 0.85% | -45.0% |
| Q2 2017 | $4,239,000 | +92.2% | 245,000 | +22.5% | 1.55% | +51.1% |
| Q1 2017 | $2,206,000 | – | 200,000 | – | 1.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |